Program
cariprazine
Also written as “Cariprazine”, “MP-214 3mg” and “MP-214 6mg”.
Its studies are mostly in Schizophrenia · Depressive Disorder, Major · Bipolar Disorder · Mania · Depression, led by 7 companies.
Drug pageCariprazine: every studyMany companies study it; this page follows only the 41 they lead. All 53 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 291 open or running | phase 3since Jan 27, 2010 | Nov 27, 2006 | Mar 2027phase 3 · NCT04777357 |
| Tanabe Pharmaits history only | 60 open or running | phase 3since Jun 19, 2012 | Mar 15, 2009 | none ahead |
| Gedeon Richter Plc.its history only | 21 open or running | phase 3since Jan 24, 2019 | Jun 13, 2014 | Dec 15, 2026phase 3 · NCT03817502 |
| Bostal Drug Deliveryits history only | 11 open or running | phase 3since Jul 15, 2026 | Jul 15, 2026 | Aug 2027phase 3 · NCT07722728 |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Jul 1, 2026 | Jul 1, 2026 | none ahead |
| Mapi Pharmaits history only | 11 open or running | phase 2since Aug 28, 2025 | Aug 28, 2025 | Dec 31, 2026phase 2 · NCT07185815 |
| Whanin Pharmaceuticalits history only | 10 open or running | phase 3since Nov 26, 2021 | Nov 26, 2021 | none ahead |
Also a collaborator on its studies: Gedeon Richter.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 25 studies since Nov 27, 2006.
- Jan 28, 20162 phase 3 studies in Bipolar DisorderAbbVie · NCT02670551, NCT02670538
- Jun 5, 2018Phase 3 study in ManiaAbbVie · NCT03573297 · 901 enrolled · United States, Bulgaria, Korea, Republic of and more
- Jul 10, 2018Phase 3 study in SchizophreniaAbbVie · NCT03593213 · 587 enrolled · United States, Bulgaria, Korea, Republic of and more
- Nov 8, 20182 phase 3 studies in Depressive Disorder, MajorAbbVie · NCT03738215, NCT03739203
- Jan 24, 2019Phase 3 study in SchizophreniaGedeon Richter Plc. · NCT03817502 · 330 planned · United States, Bulgaria, Colombia and more
- Mar 19, 2020Phase 1 study in Autism Spectrum DisorderAbbVie · NCT04382885 · 24 enrolled · United States
- Feb 26, 2021Phase 3 study in DepressionAbbVie · NCT04777357 · 338 planned · United States, Puerto Rico, Russia
- Jul 7, 2021Phase 2 study in Generalized Anxiety DisorderAbbVie · NCT04965272 · United States
- Nov 26, 2021Whanin Pharmaceutical’s first study: phase 3 study in SchizophreniaNew to Whanin PharmaceuticalWhanin Pharmaceutical · NCT05168007 · 342 enrolled · Korea, Republic of
- May 6, 2022Phase 3 study in SchizophreniaAbbVie · NCT05368558 · 34 enrolled · Japan, Taiwan
- Jun 28, 2022Phase 3 study in Autism Spectrum DisorderAbbVie · NCT05439616 · 161 enrolled · United States, Puerto Rico
- Aug 28, 2025Mapi Pharma’s first study: phase 2 study in SchizophreniaNew to Mapi PharmaMapi Pharma · NCT07185815 · 24 planned · India, Israel
- Jul 1, 2026Humanis Saglık Anonim Sirketi’s first study: phase 1 study in SCHIZOPHRENIA 1 (Disorder)New to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT07691190 · 32 enrolled · India
- Jul 15, 2026Bostal Drug Delivery’s first study: phase 3 study in SchizophreniaNew to Bostal Drug DeliveryBostal Drug Delivery · NCT07722728 · 84 planned
Ahead
- Dec 15, 2026Primary completion: phase 3 study in SchizophreniaGedeon Richter Plc. · NCT03817502
- Dec 31, 2026Primary completion: phase 2 study in SchizophreniaMapi Pharma · NCT07185815
- Mar 2027Primary completion: phase 3 study in DepressionAbbVie · NCT04777357
- Aug 2027Primary completion: phase 3 study in SchizophreniaBostal Drug Delivery · NCT07722728
TargetBeta
“Dopamine D3 receptor modulator; Dopamine D2 receptor modulator”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| rotigotinerule | UCB | phase 4 | 64 |
| Pramipexolerule | Boehringer Ingelheim | phase 4 | 44 |
| ABBV-932 | AbbVie | phase 2 | 10 |
Studies
All 41 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07722728Schizophrenia | 3 | Not yet recruiting | Bostal Drug Delivery | Aug 2027 | 84 |
| NCT07691190SCHIZOPHRENIA 1 (Disorder) · India | 1 | Completed | Humanis Saglık Anonim Sirketi | Jun 2, 2026 | 32 |
| NCT07185815Schizophrenia · India, Israel | 2 | Recruiting | Mapi Pharma | Dec 31, 2026 | 24 |
| NCT05439616Autism Spectrum Disorder · United States, Puerto Rico | 3 | Completed | AbbVie | Oct 4, 2024 | 161 |
| NCT05368558Schizophrenia · Japan, Taiwan | 3 | Terminated | AbbVie | Sep 20, 2024 | 34 |
| NCT05168007Schizophrenia · Korea, Republic of | 3 | UNKNOWN | Whanin Pharmaceutical | Jul 17, 2023 | 342 |
| NCT04965272Generalized Anxiety Disorder · United States | 2 | Withdrawn | AbbVie | Aug 24, 2021 | 0 |
| NCT04777357Depression · United States, Puerto Rico, Russia | 3 | Recruiting | AbbVie | Mar 2027 | 338 |
| NCT04382885Autism Spectrum Disorder · United States | 1 | Completed | AbbVie | Dec 10, 2021 | 24 |
| NCT03817502Schizophrenia · United States, Bulgaria, Colombia and more | 3 | Recruiting | Gedeon Richter Plc. | Dec 15, 2026 | 330 |
| NCT03739203Depressive Disorder, Major · United States, Canada, Czechia and more | 3 | Completed | AbbVie | Sep 6, 2021 | 752 |
| NCT03738215Depressive Disorder, Major · United States, Bulgaria, Estonia and more | 3 | Completed | AbbVie | Sep 30, 2021 | 759 |
| NCT03593213Schizophrenia · United States, Bulgaria, Korea, Republic of and more | 3 | Terminated | AbbVie | Feb 11, 2021 | 587 |
| NCT03573297Mania · United States, Bulgaria, Korea, Republic of and more | 3 | Completed | AbbVie | Sep 5, 2022 | 901 |
| NCT02670551Bipolar Disorder · United States, Bulgaria, Estonia and more | 3 | Completed | AbbVie | Jul 19, 2017 | 488 |
| NCT02670538Bipolar Disorder · United States, Bulgaria, Croatia and more | 3 | Completed | AbbVie | Jan 18, 2018 | 493 |
| NCT02165098Pharmacokinetic Profile · United Kingdom | 1 | Completed | Gedeon Richter Plc. | Feb 2016 | 160 |
| NCT01838876Depressive Disorder, Major · United States, Puerto Rico | 3 | Completed | AbbVie | Jul 27, 2015 | 442 |
| NCT01715805Depressive Disorder, Major · United States, Puerto Rico | 3 | Completed | AbbVie | Jun 24, 2016 | 1,022 |
| NCT01626885Schizophrenia · Japan | 3 | Completed | Tanabe Pharma | Jun 2014 | 42 |
| NCT01626872Schizophrenia · Japan, South Korea, Taiwan | 3 | Completed | Tanabe Pharma | Oct 2016 | 254 |
| NCT01626859Schizophrenia · Japan | 3 | Completed | Tanabe Pharma | Aug 2013 | 38 |
| NCT01625897Schizophrenia · Japan | 3 | Completed | Tanabe Pharma | Mar 2015 | 125 |
| NCT01625000Schizophrenia · Japan, South Korea, Taiwan | 3 | Completed | Tanabe Pharma | Aug 2015 | 512 |
| NCT01469377Depressive Disorder, Major · United States, Estonia, Finland and more | 2 | Completed | AbbVie | Dec 12, 2013 | 819 |
| NCT01412060Schizophrenia · United States, India, Romania and more | 3 | Completed | AbbVie | Sep 3, 2014 | 765 |
| NCT01396447Bipolar Disorder · United States, Bulgaria, Canada and more | 2 | Completed | AbbVie | Jan 10, 2014 | 584 |
| NCT01376076Schizophrenia · United States | 1 | Completed | AbbVie | Feb 2012 | 129 |
| NCT01104779Schizophrenia · United States, Colombia, India and more | 3 | Completed | AbbVie | Dec 15, 2011 | 446 |
| NCT01104792Schizophrenia · United States, Colombia, India and more | 3 | Completed | AbbVie | Jan 31, 2013 | 752 |
| NCT01104766Schizophrenia · United States, Romania, Russian Federation and more | 3 | Completed | AbbVie | Dec 20, 2011 | 617 |
| NCT01059539Mania · United States, Hungary, Poland and more | 3 | Completed | AbbVie | Feb 29, 2012 | 403 |
| NCT01058668Mania · United States, Croatia, Romania and more | 3 | Completed | AbbVie | Dec 2011 | 497 |
| NCT01058096Bipolar Disorder · United States, India | 3 | Completed | AbbVie | Jul 2011 | 323 |
| NCT00862992Schizophrenia · Japan | 2 | Completed | Tanabe Pharma | Sep 2009 | 34 |
| NCT00854100Depressive Disorder, Major · United States | 2 | Completed | AbbVie | Dec 6, 2010 | 231 |
| NCT00852202Bipolar Disorder · United States | 2 | Completed | AbbVie | Jun 15, 2010 | 234 |
| NCT00839852Schizophrenia · United States, India, Malaysia and more | 2 | Completed | AbbVie | Aug 31, 2010 | 97 |
| NCT00694707Schizophrenia · United States, India, Malaysia and more | 2 | Completed | AbbVie | Aug 31, 2009 | 732 |
| NCT00488618Bipolar Disorder · United States | 2 | Completed | AbbVie | Jul 2008 | 238 |
| NCT00404573Schizophrenia · United States | 2 | Completed | AbbVie | Aug 2007 | 375 |
How it is read
Names in the registry
- “Cariprazine”, 25 entries
- “MP-214 3mg”, 3 entries
- “MP-214 6mg”, 3 entries
- “MP-214 9mg”, 3 entries
- “MP-214”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 21 studies
- Depressive Disorder, Major, 6 studies
- Bipolar Disorder, 6 studies
- Mania, 3 studies
- Depression, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.